Topping off a series A round that began in the summer of 2015 with $55 million, E-Scape Bio Inc. raised $63 million in total that CEO Leon Chen told BioWorld should carry the firm into proof-of-concept work that takes aim at the apolipoprotein E4 (ApoE4) protein structure in Alzheimer's disease (AD).